ArticleEuropean journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery2026
Differential Survival Outcomes of Satisfactory Tumour Response (ypStage I) Following Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Immunochemotherapy of Oesophageal Squamous Cell Cancer.
Article in European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectivesNeoadjuvant chemoradiotherapy (NCRT) remains the standard for locally advanced oesophageal squamous cell carcinoma. Emerging evidence on neoadjuvant immunochemotherapy (NICT) has shown promising short-term efficacy, although it is associated with lower pathological complete response rates. The retrospective study aims to compare recurrence patterns and survival outcomes of satisfactory tumour response (ypStage I/ypT0-2N0M0) after either modality followed by surgery.
methodsWe analysed ypStage I patients who underwent McKeown oesophagectomy at Sun Yat-sen University Cancer Center (July 2009-July 2022). Propensity score matching (1:1) balanced baseline characteristics. Overall survival (OS), disease-free survival (DFS), and recurrence patterns were analysed.
resultsTotally, 156 cases of NCRT, 63 cases of NICT were included. After matching (63 pairs), recurrence patterns diverged significantly: the NICT group had predominant regional lymph node recurrence (100% vs 22.73%, P < .001), larger recurrent lesions (median 41 vs 24 mm, P = .011), and lower distant metastasis (42.86% vs 86.36%, P = .021). It also showed superior 3-year OS (90.07% vs 83.44%, P = .021), 3-year DFS (88.89% vs 76.03%, P = .011), and better conditional survival beyond 2 years (P = .032, P = .008).
conclusionsRecurrence patterns differ between the two modalities in ypStage I patients. NICT was associated with better survival. Studies comparing the two modalities should focus more on survival rather than tumour response in oesophageal squamous cell cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.